University of Massachusetts Center for Clinical and Translational Science

我们建立了马萨诸塞州大学临床和转化科学中心 （UMCCTS），其中包括五个麻省大学校园。在运作上，该中心位于大学的 伍斯特校区，由医学院管理。该中心作为“学术之家”， 麻省大学所有校区的临床和转化科学家。CTSA计划将建立临床和 以世界级基础科学为基础的转化研究，这一点得到了世界级基础科学奖的证明 2006年诺贝尔生理学或医学奖授予克雷格梅洛，阿尔伯特拉斯克奖授予维克托安布罗斯 2008年UMCCTS的目标是：1）通过招募，加速早期转化（TI）研究 杰出的T1研究领导者;建立创新研究核心设施;并开发新的 疗法，设备和基于麻省大学发现的干预措施; 2）整合独特的临床网络， 在新英格兰中部和马萨诸塞州广泛开展研究和医疗保健服务，以建立和扩大 T2（临床有效性研究）和T3（实施和传播研究）能力， 招募优秀的T2和T3研究领导者，并开发创新的T2/T3核心设施;以及 加强病人和社区的外展和参与临床/人口为基础的研究; 3） UMCCTS将与麻省大学系统的所有校区和学校合作， 项目，课程和教师支持系统，促进临床和转化研究的职业生涯。 州长德瓦尔帕特里克和马萨诸塞州立法机构最近颁布了一项立法，承诺提供10亿美元 国家投资将直接用于英联邦的生命科学。用9000万美元的种子 资金，大学已经建立了麻省大学先进的治疗集群（UMATC），其中包括 RNA治疗研究所，干细胞生物学和再生医学中心，以及基因 治疗中心。UATC加入了马萨诸塞州生物实验室，迈耶斯初级保健研究所， 和联邦医学，四个创新的组成部分，很少发现在学术中心， 从快速实验台到床边，再到临床和转化研究的社区发现。 相关性（参见说明）： 马萨诸塞州大学临床和转化科学中心（UMCCTS）将改变 通过为所有大学临床研究提供一个“学术之家”， investigators. UMCCTS将提供强有力的试点赠款计划，全面的教育和职业 发展计划和创新的核心设施，以支持和培养临床研究者。

We have established the University of Massachusetts Center for Clinical and Translational Science (UMCCTS) which includes the five UMass campuses. Operationally, the Center is located at the University's Worcester campus and managed by the School of Medicine. The Center serves as the "academic home" for clinical and translational scientists across all UMass campuses. The CTSA program will build clinical and translational research upon a foundation of world class basic science as evidenced by the award of the Nobel Prize in Physiology or Medicine to Craig Mello in 2006 and the Albert Lasker Award to Victor Ambros in 2008. The UMCCTS aims are to: 1) Accelerate early phase translational (Tl) studies by recruiting outstanding T1 research leaders; establishing innovative research core facilities; and developing new therapies, devices, and interventions based upon UMass discoveries; 2) Integrate unique networks of clinical research and healthcare delivery in Central New England and Massachusetts at-large to build and expand T2 (clinical effectiveness research) and T3 (implementation and dissemination research) capacity by recruiting outstanding T2 and T3 research leaders, and by developing innovative T2/T3 core facilities; and enhancing patient and community outreach and participation in clinical/population-based research; 3) The UMCCTS will work collaboratively with all campuses and schools ofthe UMass system in developing programs, curricula, and faculty support systems that promote careers in clinical and translational research. Governor Deval Patrick and the Massachusetts Legislature recently enacted legislation committing $1 billion in state investment to be directed to the Life Sciences in the Commonwealth. With $90 million in seed funding, the University has established the UMass Advanced Therapeutics Cluster (UMATC) which includes the RNA Therapeutics Institute, the Center for Stem Cell Biology and Regenerative Medicine, and the Gene Therapy Center. The UMATC joins the Massachusetts Biologic Laboratories, Meyers Primary Care Institute, and Commonwealth Medicine, four innovative components that are rarely found in academic centers, to speed bench to bedside to community discoveries in clinical and translational research. RELEVANCE (See instructions): The University of Massachusetts Center for Clinical and Translational Science (UMCCTS) will transform the conduct of clinical and translational research by providing an "academic home" for all university clinical investigators. The UMCCTS will provide robust pilot grant programs, comprehensive education and career development programs, and innovative core facilities to support and nurture clinical investigators.